Needham analyst David Saxon has maintained their neutral stance on BLCO stock, giving a Hold rating yesterday.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
David Saxon has given his Hold rating due to a combination of factors affecting Bausch + Lomb Corporation. The company’s first-quarter results for 2025 fell short of expectations, primarily due to charges related to the enVista recall, which negatively impacted profitability. Although management has increased its revenue guidance for 2025, this is tempered by a reduction in EBITDA guidance.
Additionally, there is uncertainty surrounding potential tariff impacts, estimated to be around $60 million in the second half of 2025, which adds to the cautious outlook. Furthermore, the ongoing separation from its parent company, Bausch Health Companies, introduces additional uncertainty. These factors collectively contribute to the Hold rating, as they present both potential risks and opportunities for the company’s future performance.
According to TipRanks, Saxon is an analyst with an average return of -3.9% and a 31.49% success rate. Saxon covers the Healthcare sector, focusing on stocks such as DENTSPLY SIRONA, Globus Medical, and Alcon.
In another report released yesterday, Barclays also maintained a Hold rating on the stock with a $19.00 price target.